Advertisement

International Journal of Hematology

, Volume 109, Issue 2, pp 175–186 | Cite as

Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma

  • Satoshi YamasakiEmail author
  • Dai Chihara
  • Sung-Won Kim
  • Takahito Kawata
  • Shuichi Mizuta
  • Hiroatsu Ago
  • Takaaki Chou
  • Takahisa Yamane
  • Hitoji Uchiyama
  • Tatsuo Oyake
  • Katsuhiro Miura
  • Bungo Saito
  • Hirofumi Taji
  • Hirohisa Nakamae
  • Toshihiro Miyamoto
  • Takahiro Fukuda
  • Junya Kanda
  • Yoshiko Atsuta
  • Ritsuro Suzuki
Original Article
  • 125 Downloads

Abstract

High-dose chemotherapy with autologous stem cell transplantation (HDC-ASCT) is an option for patients with peripheral T-cell lymphoma (PTCL); however, neither prospective nor retrospective studies support proceeding with ASCT upfront, and the timing of HDC-ASCT remains controversial. We retrospectively analyzed the risk factors for outcomes of 570 patients with PTCL, including PTCL not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL), who received ASCT for frontline consolidation (n = 98 and 75, respectively) or alternative therapies after either relapse (n = 112 and 75) or primary induction failure (PIF; n = 127 and 83) between 2000 and 2015. Significant risk factors for overall survival (OS) after upfront ASCT were a ≥ 2 prognostic index for T-cell lymphoma (P < 0.001) and partial response (PR) at ASCT (P = 0.041) in PTCL-NOS patients, and > 60 years of age (P = 0.0028) and PR at ASCT (P = 0.0013) in AITL patients. Performance status of ≥ 2 at ASCT (P < 0.001), receiving ≥ 3 regimens before ASCT (P = 0.018), and PR at ASCT (P = 0.018) in PTCL-NOS patients and > 60 years of age at ASCT (P = 0.0077) in AITL patients were risk factors for OS after ASCT with a chemosensitive PIF status. Strategies that carefully select PTCL patients may allow identification of individuals suitable for ASCT.

Keywords

Autologous stem cell transplantation Peripheral T-cell lymphoma not otherwise specified Angioimmunoblastic T-cell lymphoma 

Notes

Acknowledgements

We thank the patients and clinical staff for their participation in the study. We are very grateful to the Japanese Data Center for Hematopoietic Cell Transplantation for data management and the Clinical Research Institute of Kyushu Medical Hospital, Dr. Hiromi Iwasaki (Kyushu medical center), and Dr. Junji Suzumiya (Shimane University Hospital) for helpful discussions and their editorial support. We also thank Mitchell Arico from Edanz Group (http://www.edanzediting.com/ac) for editing a draft of this manuscript. This work was supported by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) of the Japan Agency for Medical Research and Development (AMED).

Funding

There are no funding/financial sources.

Compliance with ethical standards

Conflict of interest

The authors have nothing to disclose.

Supplementary material

12185_2018_2560_MOESM1_ESM.docx (32 kb)
Supplementary material 1 (DOCX 32 KB)
12185_2018_2560_MOESM2_ESM.pptx (197 kb)
Supplementary material 2 (PPTX 197 KB)

References

  1. 1.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017.Google Scholar
  2. 2.
    Karlin L, Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014;51:25–34.CrossRefGoogle Scholar
  3. 3.
    Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124–30.CrossRefGoogle Scholar
  4. 4.
    Schmitz N, de Leval L. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol. 2017;176:851–66.CrossRefGoogle Scholar
  5. 5.
    Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106–13.CrossRefGoogle Scholar
  6. 6.
    d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma:NLG-T-01. J Clin Oncol. 2012;30:3093–9.CrossRefGoogle Scholar
  7. 7.
    Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the guidelines committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23:1826–38.CrossRefGoogle Scholar
  8. 8.
    Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. 2007;18:652–627.CrossRefGoogle Scholar
  9. 9.
    Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:218–24.Google Scholar
  10. 10.
    Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31:3100–9.CrossRefGoogle Scholar
  11. 11.
    Yin J, Wei J, Xu JH, Xiao Y, Zhang YC. Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: results of a comprehensive meta-analysis. Acta Haematol. 2014;131:114–25.CrossRefGoogle Scholar
  12. 12.
    Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20:1533–8.CrossRefGoogle Scholar
  13. 13.
    Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;19:958–63.CrossRefGoogle Scholar
  14. 14.
    Yam C, Landsburg DJ, Nead KT, Lin X, Mato AR, Svoboda J, et al. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. Am J Hematol. 2016;91:672–6.CrossRefGoogle Scholar
  15. 15.
    Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29:715–23.CrossRefGoogle Scholar
  16. 16.
    Rohlfing S, Dietrich S, Witzens-Harig M, Hegenbart U, Schönland S, Luft T, et al. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. Ann Hematol. 2018;97:1241–50.CrossRefGoogle Scholar
  17. 17.
    Cheson BD. Novel therapies for peripheral T-cell non-Hodgkin’s lymphomas. Curr Opin Hematol. 2009;16:299–305.CrossRefGoogle Scholar
  18. 18.
    Maruyama D, Tobinai K, Ogura M, Uchida T, Hatake K, Taniwaki M, et al. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. Int J Hematol. 2017;106:655–65.CrossRefGoogle Scholar
  19. 19.
    Gisselbrecht C, Sibon D. New perspectives in the therapeutic approach of peripheral T-cell lymphoma. Curr Opin Oncol. 2018;30:285–91.Google Scholar
  20. 20.
    Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86:269–74.CrossRefGoogle Scholar
  21. 21.
    Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3–10.CrossRefGoogle Scholar
  22. 22.
    Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant. 2010;45:311–6.CrossRefGoogle Scholar
  23. 23.
    Han LN, Zhou J, Hirose T, Imai Y, Ishiguro T, Chou T. Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin’s lymphoma. Int J Hematol. 2006;84:174–81.CrossRefGoogle Scholar
  24. 24.
    Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, et al. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol. 2016;95:1513–9.CrossRefGoogle Scholar
  25. 25.
    Gallamini A, Stelitano C, Calvi R, Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474–9.CrossRefGoogle Scholar
  26. 26.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefGoogle Scholar
  27. 27.
    Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970–6.CrossRefGoogle Scholar
  28. 28.
    Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176:750–8.CrossRefGoogle Scholar
  29. 29.
    Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol. 2008;26:2264–71.CrossRefGoogle Scholar
  30. 30.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefGoogle Scholar
  31. 31.
    Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014;32:3048–3058.CrossRefGoogle Scholar
  32. 32.
    Cottereau AS, Becker S, Broussais F, Casasnovas O, Kanoun S, Roques M, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol. 2016;27:719–24.CrossRefGoogle Scholar
  33. 33.
    Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T, et al. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol. 2015;26:386–92.CrossRefGoogle Scholar
  34. 34.
    Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2009;27:3951–8.CrossRefGoogle Scholar
  35. 35.
    Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127:938–47.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Satoshi Yamasaki
    • 1
    Email author
  • Dai Chihara
    • 2
  • Sung-Won Kim
    • 3
  • Takahito Kawata
    • 4
  • Shuichi Mizuta
    • 5
  • Hiroatsu Ago
    • 6
  • Takaaki Chou
    • 7
  • Takahisa Yamane
    • 8
  • Hitoji Uchiyama
    • 9
  • Tatsuo Oyake
    • 10
  • Katsuhiro Miura
    • 11
  • Bungo Saito
    • 12
  • Hirofumi Taji
    • 13
  • Hirohisa Nakamae
    • 14
  • Toshihiro Miyamoto
    • 15
  • Takahiro Fukuda
    • 3
  • Junya Kanda
    • 4
  • Yoshiko Atsuta
    • 16
  • Ritsuro Suzuki
    • 17
  1. 1.Department of Hematology and Clinical Research InstituteNational Hospital Organization Kyushu Medical CenterFukuokaJapan
  2. 2.Medical Oncology Service, Center for Cancer ResearchNational Cancer Institute, National Institute of HealthBethesdaUSA
  3. 3.Division of Hematopoietic Stem Cell TransplantationNational Cancer Center HospitalTokyoJapan
  4. 4.Department of Hematology and Oncology, Graduate School of MedicineKyoto UniversityKyotoJapan
  5. 5.Department of Hematology and ImmunologyKanazawa Medical UniversityIshikawaJapan
  6. 6.Department of Hematology and OncologyShimane Prefectural Central HospitalIzumoJapan
  7. 7.Department of Hematology and OncologyNiigata Cancer Center HospitalNiigataJapan
  8. 8.Department of HematologyOsaka City General HospitalOsakaJapan
  9. 9.Department of HematologyJapanese Red Cross Kyoto Daiichi HospitalKyotoJapan
  10. 10.Division of Hematology and Oncology, Department of Internal MedicineIwate Medical UniversityMoriokaJapan
  11. 11.Department of Hematology and Rheumatology, Center of Hematoloietic Cell Transplantation and Cell TherapyNihon University School of MedicineTokyoJapan
  12. 12.Division of Hematology, Department of MedicineShowa University School of MedicineTokyoJapan
  13. 13.Department of Hematology and Cell TherapyAichi Cancer Center HospitalNagoyaJapan
  14. 14.Department of HematologyOsaka City University HospitalOsakaJapan
  15. 15.Hematology, Oncology and Cardiovascular MedicineKyushu University HospitalFukuokaJapan
  16. 16.Department of Healthcare AdministrationNagoya University Graduate School of Medicine and Japanese Data Center for Hematopoietic Cell TransplantationNagoyaJapan
  17. 17.Department of Oncology and HematologyShimane University HospitalIzumoJapan

Personalised recommendations